EyeGate Pharmaceuticals I... (EYEG)
NASDAQ: EYEG
· Real-Time Price · USD
35.64
-0.07 (-0.20%)
At close: Aug 19, 2025, 3:59 PM
35.69
0.13%
After-hours: Aug 19, 2025, 04:04 PM EDT
EyeGate Pharmaceuticals Balance Sheet Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 1.03M | 3.77M | 3.79M | 5.64M | 6.58M | 11.11M | 3.66M | 6.61M |
Short-Term Investments | 19.64M | 20.33M | 23M | 23.4M | 21.24M | n/a | n/a | n/a |
Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 65.47K | 68.4K | 28.97K | 34.37K | 36.3K | 89.25K | 90.92K | 94K |
Receivables | n/a | n/a | n/a | n/a | n/a | n/a | 311.17K | 147.1K |
Inventory | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Current Assets | 4.07M | 3M | 2.91M | 2.62M | 4.01M | 763.09K | 440.78K | 233.49K |
Total Current Assets | 24.74M | 27.11M | 29.71M | 31.65M | 31.83M | 11.87M | 4.42M | 6.99M |
Property-Plant & Equipment | 455.86K | 157.07K | 62.4K | 135.25K | 145.81K | 338.05K | 391.69K | 326.99K |
Goodwill & Intangibles | 6.69M | 6.69M | 6.69M | 6.69M | 8.8M | 13.2M | 13.2M | 13.21M |
Total Long-Term Assets | 7.21M | 6.91M | 6.78M | 6.86M | 8.98M | 13.62M | 13.68M | 13.63M |
Total Assets | 31.95M | 34.02M | 36.48M | 38.51M | 40.81M | 25.49M | 18.1M | 20.62M |
Account Payables | 282.54K | 942.49K | 415.59K | 660.41K | 268.64K | 424.89K | 292.32K | 457.35K |
Deferred Revenue | 1.25M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Short-Term Debt | 143.33K | 71.55K | 23.36K | 33.45K | 42.13K | 289.48K | 170.06K | 82.79K |
Other Current Liabilities | 1.79M | 5.2M | 5.57M | 2.83M | 1.35M | 1.24M | 974.07K | 885.46K |
Total Current Liabilities | 3.19M | 5.27M | 6.01M | 3.53M | 1.66M | 1.96M | 1.44M | 1.43M |
Long-Term Debt | 287.08K | 87.47K | 33.81K | 39.19K | 40.2K | 228.95K | 137.96K | 438.13K |
Other Long-Term Liabilities | 5.85M | 4.47M | 4.19M | 4.13M | 5.24M | 5.23M | 5.34M | 5.34M |
Total Long-Term Liabilities | 6.63M | 5.04M | 4.72M | 4.95M | 6.06M | 6.19M | 6.21M | 6.51M |
Total Liabilities | 9.82M | 10.32M | 10.72M | 8.48M | 7.71M | 8.15M | 7.65M | 7.94M |
Total Debt | 430.41K | 159.02K | 57.17K | 72.64K | 82.32K | 518.43K | 308.01K | 520.92K |
Common Stock | 272.01K | 267.68K | 267.68K | 267.68K | 267.37K | 126.19K | 70.98K | 70.98K |
Retained Earnings | -147.73M | -145.58M | -143.38M | -139.16M | -135.75M | -116.36M | -113.39M | -110.92M |
Comprehensive Income | -245.77K | -297.19K | -282.16K | -75.21K | -245.74K | -59.87K | -15.14K | 9.67K |
Shareholders Equity | 22.13M | 23.7M | 25.76M | 30.03M | 33.1M | 17.35M | 10.45M | 12.69M |
Total Investments | n/a | n/a | 23M | 23.4M | 21.24M | n/a | n/a | n/a |